^
Association details:
| Biomarker: | MYC amplification |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | RMC-5552 (mTORC1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
LB015 / 7 - Bi-steric mTORC1-selective inhibitors activate 4EBP1, suppress MYC, restore anti-tumor immunity, and cooperate with immune checkpoint inhibition to elicit tumor regression
Published date:
03/15/2023
Excerpt:
RMC-5552, a representative of the bi-steric class of selective mTORC1 inhibitor, is currently in Phase 1 clinical trials (NCT04774952). Here, we show this new class of inhibitors suppresses both S6K and 4EBP1 phosphorylation and depletes MYC protein expression in vivo in an autochthonous conditional transgenic mouse model of MYC-driven HCC and across several human patient-derived xenograft models with MYC amplification.
